Contact us in British Columbia and Yukon


Crohn’s and colitis are much more manageable when we share our experiences with each other. Education events, chapter meetings, and fundraising activities are great opportunities to meet people who are living with IBD, their families and friends, and to learn of local resources and health professionals to support you and your family.

Leadership Giving Officer, Western Canada
Susan Hampton

604-314-1151

Coordinator, Development and Community Engagement, BC/Yukon
Teri McGeachie

250-213-7761
1-800-513-8202

Coordinator, Development & Community Engagement, Southwest BC
Mishal Tahir

778-879-3473
1-800-513-8202

Woman sitting looking at her computer

Canada Wide Peer Connect Event

Ready to connect with those who understand the challenges of Crohn’s disease, ulcerative colitis, and other forms of inflammatory bowel disease (IBD)?   Join our upcoming Peer Connect ...

 • 
Virtual
 • 
A young girl watching her senior mother interact with Crohn's and Colitis Connect from a tablet device

Caregiver Peer Connect Event

Ready to connect with those who understand the challenges of being a caregiver to someone with Crohn’s disease, ulcerative colitis, and other forms of inflammatory bowel disease (IBD)?   ...

 • 
Virtual
 • 
Remember to bookmark this page.

British Columbia & Yukon Office

PO Box 47147 City Square
Vancouver, BC V5Z 4L6

bc@crohnsandcolitis.ca 1-800-513-8202

Search by Postal Code

News

Crohn’s and Colitis Canada, MS Society of Canada – Ottawa Chapter and the GottaGo! Campaign partner to improve washroom access

Crohn’s and Colitis Canada, MS Society of Canada – Ottawa Chapter and the GottaGo! Campaign partner to improve washroom access

Joint Statement from the Canadian Association of Gastroenterology and Crohn’s and Colitis Canada

Joint Statement from the Canadian Association of Gastroenterology and Crohn’s and Colitis Canada

Crohn's and Colitis Canada Announces Updated Position Statement on Biosimilar Drugs

Crohn's and Colitis Canada Announces Updated Position Statement on Biosimilar Drugs

 35 36 37 38 39 40 41 42 43 44